FULC

Fulcrum Therapeutics, Inc. (FULC) | Rumor.io

Fulcrum Therapeutics

FULC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,825

Bullish sentiment (50-day avg)100%

Price to earnings ratio-3.16

Market capitalization283.8M

Earnings per share-1.21

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-74.9M

Social

What share of all stock conversation is about FULC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 17

Fulcrum Therapeutics, Inc. ($FULC) has announced a merger agreement with Slate Medicines to advance next-generation migraine therapies.
The combined entity will operate as Slate Medicines and is expected to trade on Nasdaq under the ticker $SLTE.
The merger includes a cash dividend of approximately $3.50 per share and a private placement financing of $245 million, expected to fund operations into 2029.

Generated by AI

Sentiment

Of the messages about FULC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75.31% -8.03
Bearish	—	—	—	24.69% +8.03

Bullish· Dec 30

Fulcrum Therapeutics (FULC) has shown revenue traction, with $22.9M in quarterly revenue, indicating a strong business.
The company's NextNRG Inc. (NXXT) subsidiary has a promising BESS (Battery Energy Storage System) story, with tailwinds that could drive the stock price to $6.
Fulcrum Therapeutics' stock price has been trending upwards, with a current price of $11.99 and a price target of $13.03, indicating a high level of confidence in the company's future performance.

Bearish· Jun 2

The company's cash reserves of $330 million and lack of debt may not be enough to justify its current share price.
The absence of a pipeline and potential severance payments could lead to significant cash burn and restructuring costs.
The company's current market capitalization is significantly lower than its cash reserves, suggesting a potential undervaluation, but may not be enough to recover its value.

Generated by AI

Topics

Of the messages about FULC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.27%
Technical Analysis	—	—	0%	7%
Controversies	—	—	0%	0.1%
Analysts	—	—	0%	5.98%
Earnings	—	—	0%	3.35%
Macro	—	—	0%	0.3%

Analysts· Aug 11

Morgan Stanley upgraded Fulcrum Therapeutics to Overweight with a $34 price target.
Credit Suisse Group raised Fulcrum Therapeutics' price target to $30.
Morgan Stanley analyst Matthew Harrison upgraded Fulcrum Therapeutics from Equal-Weight to Overweight with a $34 price target.

Announcements· Aug 17

Fulcrum Therapeutics ($FULC) and Slate Medicines have agreed to combine in an all-stock merger, creating a focused next-generation migraine company operating under the Slate Medicines name.
The combined entity will trade on Nasdaq under the ticker $SLTE, with Slate stockholders owning 95% and Fulcrum holders owning 5%, who will also receive an estimated $270M cash dividend.
The merger is expected to close in Q4 2026, with Slate securing $245M in oversubscribed private placement financing to fund operations into 2029.

Technical Analysis· Aug 22

$FULC has broken above the 200ema on the daily chart and is trending upwards.
The 6 level is considered a last line of defense for $FULC, and a break above it could lead to a significant spike in price.
$FULC is showing a bullish divergence, which could indicate a possible push in price coming.

Generated by AI

Community

Of the messages about FULC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	29.45%
Newcomers	—	—	100%	70.55%

Regulars· Feb 24

The Phase 1b PIONEER trial of Pociredir in Sickle Cell Disease showed a positive 12-week result, with HbF increasing from 7.1% to 19.3% at Week 12, and no treatment-related serious adverse events.
Fulcrum Therapeutics raised $164.2M in funding, adding to its cash reserves of $352.3M, which will provide a runway into 2029.
The company announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial, with HbF increasing by 12.2% and hemoglobin increasing by 1.1 g/dL in 12 weeks.

Newcomers· Aug 17

The merger between Fulcrum Therapeutics and Slate Medicines will create a focused next-generation migraine company, with Fulcrum shareholders receiving an estimated $270 million cash dividend and 5% ownership in the combined entity.
The combined entity will operate as Slate Medicines and is expected to trade on the Nasdaq under the ticker $SLTE, with Slate Medicines securing commitments for an oversubscribed concurrent private placement of $245 million.
Fulcrum Therapeutics' shareholders will receive a special dividend of approximately $3.50 per share, with the company's remaining net cash and shell value estimated at around $0.25-$0.30 per share.

Generated by AI

News

Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

1mo agoBarchart.com

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contributing its drug assets, while new investors are supplying $245 million. Legacy Slate holders would own approximately 55.9% of the combined company, PIPE investors 39.1%, and legacy Fulcrum holders 5%, […]

1mo agoYahoo Finance Singapore

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

1mo agoBarchart.com

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations

1mo agoBarchart.com

Also Discussed

Investors talking about FULC also mention

#	Name	Attention
1	BeyondSpring Inc.BYSI	0%0
2	Bicycle Therapeutics plc - ADRBCYC	0%0
3	Foghorn Therapeutics Inc.FHTX	0%new
4	Flora Growth Corp.FLGC	0%new
5	NanoVibronix, Inc.NAOV	0%0
6	4D Molecular Therapeutics, Inc.FDMT	0%new
7	Virpax Pharmaceuticals Inc.VRPX	0%0
8	Innoviva Inc.INVA	0%new
9	ERYP - ERYTECH Pharma S.A.	——
10	MORF - Morphic Holding, Inc.	——

Fulcrum Therapeutics, Inc.

Healthcare
Biotechnology

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.

Website

Location

26 Landsdowne Street

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about FULC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 17

Fulcrum Therapeutics, Inc. ($FULC) has announced a merger agreement with Slate Medicines to advance next-generation migraine therapies.
The combined entity will operate as Slate Medicines and is expected to trade on Nasdaq under the ticker $SLTE.
The merger includes a cash dividend of approximately $3.50 per share and a private placement financing of $245 million, expected to fund operations into 2029.

Generated by AI

Sentiment

Of the messages about FULC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75.31% -8.03
Bearish	—	—	—	24.69% +8.03

Bullish· Dec 30

Fulcrum Therapeutics (FULC) has shown revenue traction, with $22.9M in quarterly revenue, indicating a strong business.
The company's NextNRG Inc. (NXXT) subsidiary has a promising BESS (Battery Energy Storage System) story, with tailwinds that could drive the stock price to $6.
Fulcrum Therapeutics' stock price has been trending upwards, with a current price of $11.99 and a price target of $13.03, indicating a high level of confidence in the company's future performance.

Bearish· Jun 2

The company's cash reserves of $330 million and lack of debt may not be enough to justify its current share price.
The absence of a pipeline and potential severance payments could lead to significant cash burn and restructuring costs.
The company's current market capitalization is significantly lower than its cash reserves, suggesting a potential undervaluation, but may not be enough to recover its value.

Generated by AI

Topics

Of the messages about FULC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.27%
Technical Analysis	—	—	0%	7%
Controversies	—	—	0%	0.1%
Analysts	—	—	0%	5.98%
Earnings	—	—	0%	3.35%
Macro	—	—	0%	0.3%

Analysts· Aug 11

Morgan Stanley upgraded Fulcrum Therapeutics to Overweight with a $34 price target.
Credit Suisse Group raised Fulcrum Therapeutics' price target to $30.
Morgan Stanley analyst Matthew Harrison upgraded Fulcrum Therapeutics from Equal-Weight to Overweight with a $34 price target.

Announcements· Aug 17

Fulcrum Therapeutics ($FULC) and Slate Medicines have agreed to combine in an all-stock merger, creating a focused next-generation migraine company operating under the Slate Medicines name.
The combined entity will trade on Nasdaq under the ticker $SLTE, with Slate stockholders owning 95% and Fulcrum holders owning 5%, who will also receive an estimated $270M cash dividend.
The merger is expected to close in Q4 2026, with Slate securing $245M in oversubscribed private placement financing to fund operations into 2029.

Technical Analysis· Aug 22

$FULC has broken above the 200ema on the daily chart and is trending upwards.
The 6 level is considered a last line of defense for $FULC, and a break above it could lead to a significant spike in price.
$FULC is showing a bullish divergence, which could indicate a possible push in price coming.

Generated by AI

Community

Of the messages about FULC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	29.45%
Newcomers	—	—	100%	70.55%

Regulars· Feb 24

The Phase 1b PIONEER trial of Pociredir in Sickle Cell Disease showed a positive 12-week result, with HbF increasing from 7.1% to 19.3% at Week 12, and no treatment-related serious adverse events.
Fulcrum Therapeutics raised $164.2M in funding, adding to its cash reserves of $352.3M, which will provide a runway into 2029.
The company announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial, with HbF increasing by 12.2% and hemoglobin increasing by 1.1 g/dL in 12 weeks.

Newcomers· Aug 17

The merger between Fulcrum Therapeutics and Slate Medicines will create a focused next-generation migraine company, with Fulcrum shareholders receiving an estimated $270 million cash dividend and 5% ownership in the combined entity.
The combined entity will operate as Slate Medicines and is expected to trade on the Nasdaq under the ticker $SLTE, with Slate Medicines securing commitments for an oversubscribed concurrent private placement of $245 million.
Fulcrum Therapeutics' shareholders will receive a special dividend of approximately $3.50 per share, with the company's remaining net cash and shell value estimated at around $0.25-$0.30 per share.

Generated by AI

Fulcrum Therapeutics

Social

Aug 17

Bullish· Dec 30

Bearish· Jun 2

Analysts· Aug 11

Announcements· Aug 17

Technical Analysis· Aug 22

Regulars· Feb 24

Newcomers· Aug 17

Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations

Also Discussed

Fulcrum Therapeutics, Inc.

Company Information

Location

Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations

Also Discussed

Social

Aug 17

Bullish· Dec 30

Bearish· Jun 2

Analysts· Aug 11

Announcements· Aug 17

Technical Analysis· Aug 22

Regulars· Feb 24

Newcomers· Aug 17